A Follow-up Study of Preterm Infants Given Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants

Huang T. Kuo, Hong C. Lin, Chang H. Tsai, I. C. Chouc, Tsu F. Yeh

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Objective: Our study of early intratracheal instillation of budesonide using surfactant as vehicle showed a significant decrease in death or chronic lung disease (CLD) in preterm infants with severe respiratory distress syndrome (RDS). We now report the long-term outcome at about 2 to 3 years of age. Study design: Of the 75 potential survivors, 67 (90%) were studied (35 budesonide-treated, 32 control). All infants had birth weight <1500 g and had severe RDS requiring intermittent mechanical ventilation shortly after birth. The treated group received a mixture of budesonide and surfactant every 8 hours. The control group received only surfactant. Results: The physical growth and the neurological examinations were comparable between the groups at follow-up. Infants in the group treated with budesonide tended to have higher PDI and MDI scores than infants in the control group (79 ± 20 vs 74 ± 18 and 80 ± 19 vs 75 ± 20), but these differences were not statistically significant. The incidence of neurodevelopmental impairment was 11 (31%) in the treated group and 13 (40%) in the control group (P = .367). Conclusions: Early intratracheal instillation of budesonide using surfactant as a vehicle significantly improved pulmonary outcome without causing long-term adverse effects.

Original languageEnglish
Pages (from-to)537-541
Number of pages5
JournalJournal of Pediatrics
Volume156
Issue number4
DOIs
Publication statusPublished - Apr 1 2010
Externally publishedYes

Fingerprint

Budesonide
Premature Infants
Surface-Active Agents
Lung Diseases
Chronic Disease
Control Groups
Neurologic Examination
Artificial Respiration
Birth Weight
Parturition
Lung
Incidence
Growth

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

A Follow-up Study of Preterm Infants Given Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants. / Kuo, Huang T.; Lin, Hong C.; Tsai, Chang H.; Chouc, I. C.; Yeh, Tsu F.

In: Journal of Pediatrics, Vol. 156, No. 4, 01.04.2010, p. 537-541.

Research output: Contribution to journalArticle

@article{12f9ea79e58c47fbaf120f8a3b7712ff,
title = "A Follow-up Study of Preterm Infants Given Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants",
abstract = "Objective: Our study of early intratracheal instillation of budesonide using surfactant as vehicle showed a significant decrease in death or chronic lung disease (CLD) in preterm infants with severe respiratory distress syndrome (RDS). We now report the long-term outcome at about 2 to 3 years of age. Study design: Of the 75 potential survivors, 67 (90{\%}) were studied (35 budesonide-treated, 32 control). All infants had birth weight <1500 g and had severe RDS requiring intermittent mechanical ventilation shortly after birth. The treated group received a mixture of budesonide and surfactant every 8 hours. The control group received only surfactant. Results: The physical growth and the neurological examinations were comparable between the groups at follow-up. Infants in the group treated with budesonide tended to have higher PDI and MDI scores than infants in the control group (79 ± 20 vs 74 ± 18 and 80 ± 19 vs 75 ± 20), but these differences were not statistically significant. The incidence of neurodevelopmental impairment was 11 (31{\%}) in the treated group and 13 (40{\%}) in the control group (P = .367). Conclusions: Early intratracheal instillation of budesonide using surfactant as a vehicle significantly improved pulmonary outcome without causing long-term adverse effects.",
author = "Kuo, {Huang T.} and Lin, {Hong C.} and Tsai, {Chang H.} and Chouc, {I. C.} and Yeh, {Tsu F.}",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.jpeds.2009.10.049",
language = "English",
volume = "156",
pages = "537--541",
journal = "Journal of Pediatrics",
issn = "0022-3476",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - A Follow-up Study of Preterm Infants Given Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants

AU - Kuo, Huang T.

AU - Lin, Hong C.

AU - Tsai, Chang H.

AU - Chouc, I. C.

AU - Yeh, Tsu F.

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Objective: Our study of early intratracheal instillation of budesonide using surfactant as vehicle showed a significant decrease in death or chronic lung disease (CLD) in preterm infants with severe respiratory distress syndrome (RDS). We now report the long-term outcome at about 2 to 3 years of age. Study design: Of the 75 potential survivors, 67 (90%) were studied (35 budesonide-treated, 32 control). All infants had birth weight <1500 g and had severe RDS requiring intermittent mechanical ventilation shortly after birth. The treated group received a mixture of budesonide and surfactant every 8 hours. The control group received only surfactant. Results: The physical growth and the neurological examinations were comparable between the groups at follow-up. Infants in the group treated with budesonide tended to have higher PDI and MDI scores than infants in the control group (79 ± 20 vs 74 ± 18 and 80 ± 19 vs 75 ± 20), but these differences were not statistically significant. The incidence of neurodevelopmental impairment was 11 (31%) in the treated group and 13 (40%) in the control group (P = .367). Conclusions: Early intratracheal instillation of budesonide using surfactant as a vehicle significantly improved pulmonary outcome without causing long-term adverse effects.

AB - Objective: Our study of early intratracheal instillation of budesonide using surfactant as vehicle showed a significant decrease in death or chronic lung disease (CLD) in preterm infants with severe respiratory distress syndrome (RDS). We now report the long-term outcome at about 2 to 3 years of age. Study design: Of the 75 potential survivors, 67 (90%) were studied (35 budesonide-treated, 32 control). All infants had birth weight <1500 g and had severe RDS requiring intermittent mechanical ventilation shortly after birth. The treated group received a mixture of budesonide and surfactant every 8 hours. The control group received only surfactant. Results: The physical growth and the neurological examinations were comparable between the groups at follow-up. Infants in the group treated with budesonide tended to have higher PDI and MDI scores than infants in the control group (79 ± 20 vs 74 ± 18 and 80 ± 19 vs 75 ± 20), but these differences were not statistically significant. The incidence of neurodevelopmental impairment was 11 (31%) in the treated group and 13 (40%) in the control group (P = .367). Conclusions: Early intratracheal instillation of budesonide using surfactant as a vehicle significantly improved pulmonary outcome without causing long-term adverse effects.

UR - http://www.scopus.com/inward/record.url?scp=77949484633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949484633&partnerID=8YFLogxK

U2 - 10.1016/j.jpeds.2009.10.049

DO - 10.1016/j.jpeds.2009.10.049

M3 - Article

VL - 156

SP - 537

EP - 541

JO - Journal of Pediatrics

JF - Journal of Pediatrics

SN - 0022-3476

IS - 4

ER -